Skip to content

Evaluation of clinical guideline and establishment of evidence for the diagnosis and treatment of primary hyperaldosteronism in Japan.

Evaluation of clinical guideline and establishment of evidence for the diagnosis and treatment of primary hyperaldosteronism in Japan. - PHAS-J3

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000008844
Enrollment
2700
Registered
2012-09-05
Start date
2012-09-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Primary aldosteronism

Interventions

Sponsors

National Hospital Organization
Lead Sponsor
The Japan Endocrine Society
Collaborator

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Hypertensive patients in the outpatient clinics and hospitals, who full-fill the following 1) or 2) criteria: 1)treated hypertensive patients 2)untreated hypertensive patients with systolic blood pressure higher than 140mmHg or diastolic blood pressure higher than 90mmHg according to the guideline of the Japan Society of Hypertension

Exclusion criteria

Exclusion criteria: 1)pregnant patients 2)patients taking aldosterone antagonist within the last one month 3)patients with the following diseases: (1)secondary hypertension (renal hypertension,renovascular hypertension, primary aldosteronism, Cushing's syndrome, pheochromocytoma, etc) (2)patients whom the attending doctors decides not suitable for the entry because of the unstable stage of the following complications: coronary diseases, arrhythmia, severe valvular diseases, cerebrovascular diseases, acute and chronic renal failure (serum Cr higher than 3mg/dl), acute and chronic liver diseases 4) Patients whom the attending doctor decides not suitable for the entry of the study.

Design outcomes

Primary

MeasureTime frame
1)Adherance of clinical guideline for PA 2)Establishment of standard medication in PA and Aldosterone-rerated hypertension.

Secondary

MeasureTime frame
1)Implementation rate of each diagnostic procedure 2)Successful rate of the localization 3) Comparison of the effects of medical treatments and surgical treatment

Countries

Japan

Contacts

Public ContactMitsuhide Naruse

National Hospital Organization, Kyoto Medical Center Clinical Research Institute for Endocrine and Metabolic Diseases

yawata.rinshokenkyubu@gmail.com075-641-9161

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026